Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BuMelTT Conditioning for Autologous Stem Cell Transplant in Lymphoma
NCT00238433Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Mar 2005
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, melphalan, thiotepa in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), sponsored by OHSU Knight Cancer Institute. Started Mar 2005; status: completed.
02
Drugs
busulfanmelphalanthiotepa
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00238433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238433.